IP Library Granted Patent US 8,114,849
Granted Patent B2
US 8,114,849 · App. 11/739,739 · Granted Feb 14, 2012

Retinal dystrophy-associated protein and uses thereof

Assignees: Novartis AG; Universite de Strasbourg
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,114,849
App. No.
11/739,739
Granted
Feb 14, 2012
Kind
B2
Abstract

Disclosed are methods and compositions for early diagnosis, monitoring and treatment of retinal dystrophy, age-related macular degeneration, Bardet-Biedel syndrome, Bassen-kornzweig syndrome, best disease, choroidema, gyrate atrophy, congenital amourosis, refsun syndrome, stargardt disease and Usher syndrome. In particular, the invention relates to a protein, termed “Rdcvf1,” that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with non-sufferers, antibodies which recognize this protein, and methods for diagnosing such conditions.

Claims (6)

1. A method of increasing the amount of Rod-Derived Cone Viability Factor (RDCVF) 1 polypeptide or RDCVF 2 polypeptide in the retinal cells of a subject suffering from retinitis pigmentosa characterized by the loss of the RDCVF 1 polypeptide or the RDCVF 2 polypeptide, the method comprising introducing a viral vector comprising a nucleic acid sequence encoding the RDCVF1 polypeptide or the RDCVF2 polypeptide into the retinal cells of the subject, wherein the nucleic acid is operably linked to a transcription control sequence, whereby expression of the nucleic acid in the retinal cells increases the amount of the RDCVF1 polypeptide or the RDCVF2 polypeptide.

2. The method of claim 1 further comprising the step of measuring the difference in the amount of the RDCVF1 polypeptide or the RDCVF2 polypeptide after introducing the viral vector compared to the amount of the RDCVF1 polypeptide or the RDCVF2 polypeptide prior to introducing the viral vector.

3. The method of claim 1 , wherein the vector is an adeno-associated virus.

4. The method of claim 1 , wherein the subject is a human.

5. The method of claim 1 , wherein the polypeptide comprises the amino acid sequence set forth in SEQ ID NO:2, 4, 6, 8, 10, 12, or 14.

6. The method of claim 1 wherein the nucleic acid comprises the nucleic acid sequence set forth in SEQ ID NO:1, 3, 5, 7, 9, 11, or 13.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Jan 21, 2021
From: WHITE OAK GLOBAL ADVISORS, LLC, AS ADMINISTRATIVE AGENT
To: WELLSTAT OPHTHALMICS CORPORATION
Reel/Frame 054983/0577 →
SECURITY AGREEMENT Recorded Sep 17, 2013
From: WELLSTAT OPHTHALMICS CORPORATION
To: PDL BIOPHARMA, INC.
Reel/Frame 031227/0182 →
SECURITY AGREEMENT Recorded Aug 15, 2013
From: WELLSTAT OPHTHALMICS CORPORATION
To: WHITE OAK GLOBAL ADVISORS, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 031030/0720 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 2, 2010
From: LEVEILLARD, THIERRY; SAHEL, JOSE ALAIN; MOHAND-SAID, SADDEK; HICKS, DAVID
To: NOVARTIS AG; UNIVERSITE LOUIS PASTEUR
Reel/Frame 024180/0767 →
CHANGE OF NAME Recorded Apr 2, 2010
From: UNIVERSITE LOUIS PASTEUR
To: UNIVERSITE DE STRASBOURG
Reel/Frame 024180/0795 →
Priority Claims (1)
FR 01 04712 · Apr 6, 2001 · national
Continuity (2)
Division 10473008
Related Publication 20080004231A1 · Jan 3, 2008